Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Viking Therapeutics a Smart Buy on the Dip?

TheMotleyFool

0 0

Is Viking Therapeutics a Smart Buy on the Dip?: https://g.foolcdn.com/editorial/images/725913/investment-presentation2-getty.jpg

Shares of Viking Therapeutics (NASDAQ: VKTX) are down about 25% from the peak they reached in mid-March. If you weren't paying close attention, you might think the clinical-stage drugmaker announced disappointing results from its lead candidate, but this wasn't the case.

Viking Therapeutics' lead candidate, VK2809, is an experimental treatment for non-alcoholic steatohepatitis (NASH). Its second most advanced program, VK2735, is aimed at metabolic disorders including obesity. The company had nothing to say about these programs last week, but its stock price still tanked.

Is Viking Therapeutics a smart buy on the dip? Here's what you should know first.

Source Fool.com

Like: 0

VKTX

Share